Matthew T. Wiley's Net Worth

-$64.2 Thousand

Estimate Recalculated Dec 4, 2024 09:06PM EST

Who is Matthew T. Wiley

Matthew T. Wiley does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Foamix Pharmaceuticals Ltd., BioXcel Therapeutics, Inc., and Menlo Therapeutics Inc..

SEC CIK

Matthew T. Wiley's CIK is 0001759703

Past Insider Trading and Trends

2024 was Matthew T. Wiley's most active year for acquiring shares with 4 total transactions. Matthew T. Wiley's most active month to acquire stocks was the month of February. 2020 was Matthew T. Wiley's most active year for disposing of shares, totalling 4 transactions. Matthew T. Wiley's most active month to dispose stocks was the month of February. 2019 saw Matthew T. Wiley paying a total of $71,783.28 for 23,282 shares, this is the most they've acquired in one year. In 2019 Matthew T. Wiley cashed out on 2,500 shares for a total of $8,200.00, their largest year based on trade value.

Loading...

Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Foamix Pharmaceuticals Ltd.

Chief Commercial Officer
Updated Mar 11, 2020
Form 4
-100.00%
-310.44K
Mar 11, 2020
Disposition
Mar 09
Form 4
1.78%
1.99K
$2.68
$5.34K
Mar 03, 2020
114.07K
Grant
Mar 02
Form 4
194.49%
137.66K
Feb 24, 2020
208.45K
Grant
Feb 24
Form 4
-3.41%
-2.50K
$3.28
-$8.20K
Jan 03, 2020
70.78K
Tax
Dec 31
Form 4
15.51%
9.84K
$2.16
$21.25K
Dec 03, 2019
73.28K
Grant
Nov 29
Form 4
26.88%
13.44K
$3.76
$50.53K
Mar 06, 2019
63.44K
Purchase
Mar 05
Form 4
150.00K
Dec 04, 2018
150.00K
Grant
Dec 03
Form 3
Nov 26, 2018
Showing 8 results

BioXcel Therapeutics, Inc.

Chief Commercial Officer
Updated Sep 17, 2024
Form 4
-1.83%
-215.00
$0.69
-$148.52
Sep 17, 2024
11.53K
Sale
ScheduledSep 15 - Sep 16
Form 4/A
-8.33%
-750.00
Sep 17, 2024
8.25K
Options
Jun 15
Form 4
11.97%
1.26K
$1.26
-$308.10
Jun 18, 2024
11.75K
Sell-Options
ScheduledJun 15 - Jun 17
Form 4
49.92%
4.99K
$2.64
-$2.66K
Apr 08, 2024
14.99K
Sell-Options
ScheduledMar 15 - Apr 04
Form 4
48.00K
Mar 16, 2023
48.00K
Grant
Mar 15
Form 4
85.00K
Jan 19, 2022
85.00K
Grant
Jan 17
Form 3
Jan 19, 2022
Showing 7 results

Menlo Therapeutics Inc.

Chief Commercial Officer
Updated Mar 11, 2020
Form 3
Mar 11, 2020
Showing 1 results